Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes

    ... myelodysplastic syndromes (MDS) were treated with thalidomide plus arsenic trioxide (ATO). Twenty-two MDS patients ... The remission was achieved in 4 patients (18.2%) receiving thalidomide/ATO, and none in the control group (p<0.05). Fifteen of 22 patients ...

    Research Article last updated 06/15/2012 - 2:20pm.

  2. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.

    ... for anemia . The immunomodulatory agents (imids) thalidomide and lenalidomide may induce transfusion ... Combining lenalidomide with other agents is not recommended. Thalidomide is not recommended. Bone Marrow ...

    Research Article last updated 10/01/2012 - 10:04am.

  3. Thalidomide

    ... use in treating a skin disease associated with leprosy. Thalidomide is being studied, either as a single agent or in combination ... the effectiveness and safety of the drug. A pilot study of thalidomide, published in 2001, found the drug improved blood counts in some ...

    Drug last updated 03/24/2016 - 12:32pm.

  4. I Was Alone With MDS Until I Connected With Others on Social Media

    ... more, I discovered that it is a derivative of a thalidomide drug. These drugs are called “ototoxic”, meaning poison to ...

    Patient Chronicle last updated 12/13/2017 - 1:57pm.

  5. Immunomodulating drugs in myelodysplastic syndromes

    ... syndrome (MDS), the immunomodulating drug (IMID) thalidomide and its derivative lenalidomide (LEN) have been used in ... demonstrated some efficacy in MDS and AML without del5q. Thalidomide also has some activity in lower-risk MDS without del5q, but its ...

    Research Article last updated 01/09/2012 - 2:00pm.

  6. Immunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes

    ... IMiDs belong to a therapeutic class whose progenitor is thalidomide , a synthetic derivative of glutamate that was initially used ... they also induce the apoptosis of neoplastic cells. Thalidomide and its derivative lenalidomide have been proposed for the ...

    Research Article last updated 01/03/2013 - 9:57am.

  7. Impact on survival of different treatments for myelodysplastic syndromes (MDS).

    ... to assess a possible survival benefit of treatment with thalidomide , valproic acid, low-dose Ara-C, antithymocyte globulin (ATG), ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Pregnancy in Bone Marrow Failure Disease

    ... Lenalidomide is a derivative medication of the drug thalidomide . In the late 1950s and early 1960s, thalidomide was used as an anti-nausea medication during pregnancy. This caused ...

    Interview last updated 01/13/2017 - 9:28am.

  9. Clinical Utility of Lenalidomide in the Treatment of Myelodysplastic Syndromes

    ... myelodysplastic syndromes (MDS). Lenalidomide, a thalidomide analog, is an immunomodulatory medication that is used in the ... in the long arm of chromosome 5, abbreviated as del(5q). Thalidomide is no longer used to treat MDS due to its side effects. The ...

    Research Review last updated 05/02/2016 - 9:12am.

  10. Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

    ... leukemia [CMML]) will include: hydroxyurea, thalidomide , hematopoietic growth factors, Zarnestra, Lenalidomide , ... of 4 weeks must have elapsed since the administration of thalidomide, Zarnestra, Revlimid, arsenic, SAHA inhibitors, or any ...

    Clinical Trial last updated 06/03/2016 - 2:24pm.